Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07744191
PHASE4

A Clinical Trial of Antiplatelets in Psoriasis

Sponsor: NYU Langone Health

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.

Official title: A Randomized, Double-blind, Placebo-controlled Crossover Trial of Antiplatelet Therapies in Psoriasis

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-09

Completion Date

2031-09

Last Updated

2026-08-05

Healthy Volunteers

No

Interventions

DRUG

Aspirin

81 mg capsule orally once daily for 4 weeks

DRUG

Clopidogrel

75 mg capsule orally once daily for 4 weeks

OTHER

Placebo

Matching placebo (microcellulose powder) capsule orally once daily for 4 weeks

Locations (1)

NYU Langone Health

New York, New York, United States